Covid-19 vaccine distribution to come up in logistics, supply challenges: Expert – Kovid-19 vaccine distribution to come up



The director of the Center for Cellular and Molecular Biology (CCMB), which works under the Scientific and Research Industrial Council (CSIR), says that many items, such as logistics and supply chain for delivery of vaccines in the country during vaccination against Kovid-19 Challenges will emerge He also said that until effective vaccines are available, efforts should be made to stop the virus from spreading.

CCMB director Dr Rakesh Mishra said that the government will do its job with the purchase and distribution of the vaccine, but the focus should be on controlling the infection. In addition, studies should be conducted for more effective anti-infective drugs to combat infection until the vaccine is available.

He said that apart from the production of Kovid-19 vaccine, there are other challenges for the delivery of goods and supplies. In India, there is no vaccination program for adults except for tetanus vaccine for pregnant women. Mishra said that there are many difficulties in vaccination of children as many people do not get vaccinated at all.

He said that at least two doses may be required for most vaccines and the second vaccine should be applied after a certain number of days. Ensuring this will be another challenge.

Mishra told ‘PTI Bhasha’ that vaccines of some companies will have to be kept at temperatures below minus 70 degrees Celsius. It will be difficult to manage at places other than big cities. He said that apart from this, there is another matter of concern that only after two-three years, it will be known whether the vaccine is really effective in the long run or not.


CCMB is developing a ‘proof of concept’ for the Kovid-19 vaccine. This is part of the agreement with Arvindo Pharma. In the ‘Proof of Concept’ it is ascertained whether a concept can be converted into reality and the practicality of its concept.

Mishra said that the goal of CSIR is to bring its efforts to “conclusion” in about three months. Mishra said that once it is ready, it will be handed over to Aurobindo Pharma for further processing.

(This news has not been edited by the NewsBust team. It has been published directly from the Syndicate feed.)


Please enter your comment!
Please enter your name here